Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Gene regulatory network wikipedia , lookup
Protein adsorption wikipedia , lookup
Bottromycin wikipedia , lookup
Two-hybrid screening wikipedia , lookup
Nuclear magnetic resonance spectroscopy of proteins wikipedia , lookup
Secreted frizzled-related protein 1 wikipedia , lookup
Protein–protein interaction wikipedia , lookup
Abstract Form (Please use the fonts, font size and styles as below) Title of the talk: Mining metastatic cancer: h-prune, a key player. M. Zollo1,2 1 2 Dipartimento di Biochimica e Biotecnologie Mediche, University of Naples, Italy CEINGE Biotecnologie Avanzate, Naples, Italy Abstract H-prune protein is a member of DHH protein family with an hitherto Exopoloyphosphatase and cAMP-PDE activity, it is found overexpressed in breast, colorectal and gastric cancers, esophageal squamous cell carcinoma; those cancer indicate that it is an independent predictor of survival, associated to depth invasion and and metastasis formation. Its expression was further analysed in medulloblastoma (MB) and lung cancer. In those cancers h-prune can be considered as a new marker of advanced-stage disease. H-prune regulates cell motility by two mode of actions: through its cAMP-PDE activity within focal adhesions, found inhibited by dipyridamole (DP), and its interactions with protein partners. Impairing in vitro nm23-H1 or GSK-3β proteinprotein interactions, we could show and impairment effect on cell motility. The correlation between h-prune expression and the aggressiveness of cancer lead us towards the development of a therapeutic chemical synthesis programme using Structure-Activity Relationship (SAR) methodology thus identifying molecules with an anti-h-prune activity. To this purpose starting from Dipyridamole (DP), a large number of DP analogues were synthesized, showing ability to suppress the h-prune induced cell motility in breast cancer cellular model. Furthermore their anti-proliferation effect was also tested in vitro. Our findings showed that two compounds inhibited h-prune cAMPPDE activity and cellular motility more effectively than DP both in vitro and in vivo in xenograft breast cancer animal models. The anti-cancer properties of one of these compounds were also tested in vivo on the MB genetic animal model (Patch +/- P53-/-). The h-prune interaction with nm23-H1 and GSK-3β plays an important role in promoting cell motility. Through NMR spectroscopy, we determined the three-dimensional structure of C-terminal protein region of h-prune (residues 353-453) and mapped the minimal region of interaction with nm23-H1. We will present the structure and then showing the use of competitive permeable peptide designed on nm23-H1 protein binding region to hprune, we were able to disrupts the formation of the nm23-H1/h-prune complex thus resulting on inhibition of cell motility, impairment of metastases formation in vivo and enhancement of neuronal differentiation in a neuroblastoma proof of concept animal model. These and other findings make of h-prune an important key player of positive controlling cancer metastasis being target for future therapeutic applications. Joint TuMIC – Metastasis Research Society - Champalimaud Foundation Conference New concepts in cancer metastasis Lisbon, June 25th – 28th 2011